CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 44 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Buprenorphine 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00763958
NCT00763958Phase 4Completed
CompareCT.gov

Relapse Prevention to Reduce HIV Among Women Prisoners

University of Alabama at Birmingham·interventional·Posted Oct 1, 2008·Updated Jun 4, 2012

In Brief

A Phase 4 clinical trial evaluating Placebo and Buprenorphine for Opioid Dependence and HIV. Completed, enrolled 44 participants.

Detailed Summary

This study is a feasibility and acceptability study assessing whether providing buprenorphine for women under criminal justice supervision leaving a controlled environment and returning to the community would prevent opioid relapse and reduce HIV risk behaviors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Dependence, HIV
Countries--
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 1, 2008
Enrollment StartMay 1, 2008
Primary CompletionSep 1, 2009
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago

Interventions

Placebodrug

Placebo to match buprenorphine administered for 3 months

Buprenorphinedrug

Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.